Ultragenyx Pharmaceutical RARE Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaboration And Royalty | $471.14M+9.5% | $481.14M+17.3% | $451.25M+16.3% | $437.15M+19.7% | $430.42M+28.6% | |
| Non Cash Royalty | $112.81M+10.7% | $111.81M+10.7% | $107.83M+13.8% | $105.97M+14.9% | $101.94M+22.5% | |
| Royalty | $303.22M+9.6% | $304.22M+10.6% | $291.81M+13.2% | $289.11M+15.0% | $276.66M+23.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ultragenyx Pharmaceutical break its business down?
- Ultragenyx Pharmaceutical (RARE) reports revenue by product across 3 parts — Collaboration And Royalty, Non Cash Royalty and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Ultragenyx Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ultragenyx Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
